Aarti Pharmalabs Limited

rs,

May 26, 2026 To, Listing/ Compliance Department BSE LTD. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 SCRIP CODE: 543748 Dear Sir/Madam, To, Listing/ Compliance De

20%

220+ Products 500+ Global Clients 63 7 3 Patents Filed Manufacturing Units USFDA Units 15-20% Global Market Share in Xanthine 50+ Export Countries 2,400+ Employees 3 State-of-the-art R&

0.32x

50+ Export Countries 2,400+ Employees 3 State-of-the-art R&D facilities 60 44 US DMF CEP 0.32x Net Debt/Equity AA- Credit rating Aarti Pharmalabs Limited 2 1COMPANY OVERVIEW 2 BUSINESS

INR 150

ited (APL) is part of the Aarti group – a diversified chemical conglomerate with group turnover of INR 150+ bn (FY26) • Globally recognized manufacturer of generic API, Xanthine derivatives and a leading p

19%

FEPRIS (Mexico) STANDALONE REVENUE (INR Mn) & EBITDA MARGINS (%) 17,714 17,976 15,112 15,021 19% 20% 24% 23% • Strategically located in western India with proximity to ports FY23 FY24 FY25

24%

xico) STANDALONE REVENUE (INR Mn) & EBITDA MARGINS (%) 17,714 17,976 15,112 15,021 19% 20% 24% 23% • Strategically located in western India with proximity to ports FY23 FY24 FY25 FY26 HIG

23%

STANDALONE REVENUE (INR Mn) & EBITDA MARGINS (%) 17,714 17,976 15,112 15,021 19% 20% 24% 23% • Strategically located in western India with proximity to ports FY23 FY24 FY25 FY26 HIGHLIGH

46%

es; Largest manufacturer of Xanthine Derivatives in India Aarti Pharmalabs Limited Domestic, 46% International, 54% 4 KEY MILESTONES 2024 • Started 21 MW solar power project at Akola, Mahar

54%

turer of Xanthine Derivatives in India Aarti Pharmalabs Limited Domestic, 46% International, 54% 4 KEY MILESTONES 2024 • Started 21 MW solar power project at Akola, Maharashtra Expansion of s

21 MW

Aarti Pharmalabs Limited Domestic, 46% International, 54% 4 KEY MILESTONES 2024 • Started 21 MW solar power project at Akola, Maharashtra Expansion of semi-commercial production block at Vapi •

7.4%

t plant scale in FY25 40+ 70+3 Products developed and manufactured on kilo-lab scale in FY25 7.4% 70+3 R&D Spend (as a percent of API+Int & CDMO sales) in FY26 122 3 65 Cr 70+3 R&D Process

25%

of FY27 Post increased capacity, target to take our global market share of currently 15-20% to 20-25%. END USE CERTIFICATIONS Others, 32% Beverages, 68% GEOGRAPHICAL SALES SPLIT (FY26) Domestic 4

Valorem Advisors Disclaimer

1

Valorem Advisors Disclaimer

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review. For further details, please feel free to contact our Investor Relations Representatives: Mr. Anuj Sonpal Valorem Advisors Tel: +91-22-3507 5100 Email: a